Lipid Management in Clinical Practice (MK-0524A-115)

Merck Sharp & Dohme (MSD)

Status: Completed

Conditions: Lipid Metabolism Disorder

Study type: Observational

Funder types: Industry

Identifiers

NCT01071278

2010_011 (Other Identifier)

0524A-115

Details and patient eligibility

About

The aim of this observational program is to generate data on the use of Tredaptive (nicotinic acid/laropiprant) for lipid management under routine medical practice conditions.

Enrollment: 2,390 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients are 18 years of age or older with lipid disorder treated with nicotinic acid/laropiprant

Exclusion criteria

• Patient is currently participating in a clinical trial

Trial design

2,390 participants in 2 patient groups

Patients treated within a disease management program

Description:

Participant prescribed Tredaptive® for dyslipidemia and also participated in a disease management program for treatment of diabetes mellitus, coronary heart disease or both.

Patients treated outside a disease management program

Description:

Participant prescribed Tredaptive® for dyslipidemia and did not participate in a disease management program for treatment of diabetes mellitus, coronary heart disease or both.